A Phase 2, Randomized, Prospective Double-Blind, Single-Center, Placebo-controlled Study to Evaluate Safety, Tolerability, Target Engagement, and Efficacy of PrimeC in Patients With Mild to Moderate Alzheimer's Disease.

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 19, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Alzheimer Disease

Interventions

DRUG

PrimeC

Ciprofloxacin and celecoxib combination extended release formulation

DRUG

Placebo

Placebo matches active drug in size, color and taste

Trial Locations (1)

RECRUITING

Rambam Health Care Campus, Haifa